XNAS
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.04 | -0.03 | +25.00% | $0 | ✅ Beat | +2.00% | -14.40% | — |
| 2026-05-15 | Q1 2026 | -0.02 | -0.05 | -150.00% | $0 | ❌ Miss | -0.29% | +34.83% | -12.36% |
Showing last 2 quarters.